First-line treatment (Tx) with subcutaneous (SC) epcoritamab (epco) plus R-CHOP in patients (pts) with high-risk diffuse large B-cell lymphoma (DLBCL): Phase 1/2 data update.

L Falchi; F Offner; D Belada; J Brody; KM Linton; Y Karimi; R Cordoba; S Snauwaert; A Abbas; LW Wang; J Wu; B Elliott; MR Clausen

First-line treatment (Tx) with subcutaneous (SC) epcoritamab (epco) plus R-CHOP in patients (pts) with high-risk diffuse large B-cell lymphoma (DLBCL): Phase 1/2 data update.

L Falchi, F Offner, D Belada, J Brody, KM Linton, Y Karimi, R Cordoba, S Snauwaert, A Abbas, LW Wang, J Wu, B Elliott, MR Clausen

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Number of pages	1
Journal	Journal of Clinical Oncology
Volume	40
Issue number	16
Publication status	Published - 1 Jun 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Falchi, L., Offner, F., Belada, D., Brody, J., Linton, KM., Karimi, Y., Cordoba, R., Snauwaert, S., Abbas, A., Wang, LW., Wu, J., Elliott, B., & Clausen, MR. (2022). First-line treatment (Tx) with subcutaneous (SC) epcoritamab (epco) plus R-CHOP in patients (pts) with high-risk diffuse large B-cell lymphoma (DLBCL): Phase 1/2 data update. Journal of Clinical Oncology, 40(16).

@article{74e3ef1a0a264a17aa21c93c5d764b8f,

title = "First-line treatment (Tx) with subcutaneous (SC) epcoritamab (epco) plus R-CHOP in patients (pts) with high-risk diffuse large B-cell lymphoma (DLBCL): Phase 1/2 data update.",

author = "L Falchi and F Offner and D Belada and J Brody and KM Linton and Y Karimi and R Cordoba and S Snauwaert and A Abbas and LW Wang and J Wu and B Elliott and MR Clausen",

year = "2022",

month = jun,

day = "1",

language = "English",

volume = "40",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "16",

}

Falchi, L, Offner, F, Belada, D, Brody, J, Linton, KM, Karimi, Y, Cordoba, R, Snauwaert, S, Abbas, A, Wang, LW, Wu, J, Elliott, B & Clausen, MR 2022, 'First-line treatment (Tx) with subcutaneous (SC) epcoritamab (epco) plus R-CHOP in patients (pts) with high-risk diffuse large B-cell lymphoma (DLBCL): Phase 1/2 data update.', Journal of Clinical Oncology, vol. 40, no. 16.

TY - JOUR

T1 - First-line treatment (Tx) with subcutaneous (SC) epcoritamab (epco) plus R-CHOP in patients (pts) with high-risk diffuse large B-cell lymphoma (DLBCL)

T2 - Phase 1/2 data update.

AU - Falchi, L

AU - Offner, F

AU - Belada, D

AU - Brody, J

AU - Linton, KM

AU - Karimi, Y

AU - Cordoba, R

AU - Snauwaert, S

AU - Abbas, A

AU - Wang, LW

AU - Wu, J

AU - Elliott, B

AU - Clausen, MR

PY - 2022/6/1

Y1 - 2022/6/1

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pure_starter&SrcAuth=WosAPI&KeyUT=WOS:000863680301984&DestLinkType=FullRecord&DestApp=WOS

M3 - Meeting Abstract

SN - 0732-183X

VL - 40

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 16

ER -

First-line treatment (Tx) with subcutaneous (SC) epcoritamab (epco) plus R-CHOP in patients (pts) with high-risk diffuse large B-cell lymphoma (DLBCL): Phase 1/2 data update.

UN SDGs

Other files and links

Cite this